Levomilnacipran (F2695; Fetzima) is the S-enantiomer of Milnacipran which is an antidepressant approved for the treatment of major depressive disorder in the United States. Milnacipran, a medication used in the clinical treatment of fibromyalgia, is a potent inhibitor of both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 420 nM, respectively. Milnacipran is mainly excreted in the urine as the parent and glucoronide (> 80%), and only a small fraction (< 10%) is metabolized via N-de-ethylation by the CYP3A4 enzyme. Milnacipran at high concentration can inhibit certain ligand-gated ion-channel (LGIC) receptors, including NMDA, 5-HT3A and nACh receptors, with IC50 of 58.4 μM, 185 μM, 14.3 μM.

纯度：≥98%

CAS：96847-54-0